Pzena Investment Management LLC Decreases Stock Holdings in Fresenius Medical Care AG & Co. KGaA $FMS

Key Points

• Pzena Investment Management LLC has decreased its holdings in Fresenius Medical Care AG & Co. KGaA by 4.6%, reducing its stake to approximately 14.66 million shares, which represents 1.4% of its investment portfolio.
• Several hedge funds, including TD Private Client Wealth LLC, significantly increased their positions in Fresenius Medical Care, with TD Private Client Wealth raising its stake by 6,380.3% in the second quarter.
• Fresenius Medical Care recently reported an EPS of $0.52, exceeding analyst expectations, with current forecasts predicting an EPS of 1.51 for the fiscal year.

Pzena Investment Management LLC decreased its position in Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Free Report) by 4.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 14,662,982 shares of the company's stock after selling 714,108 shares during the quarter. Fresenius Medical Care AG & Co. KGaA makes up 1.4% of Pzena Investment Management LLC's investment portfolio, making the stock its 25th largest position. Pzena Investment Management LLC owned 2.50% of Fresenius Medical Care AG & Co. KGaA worth $418,921,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Wayfinding Financial LLC purchased a new position in shares of Fresenius Medical Care AG & Co. KGaA in the first quarter valued at about $25,000. Spire Wealth Management purchased a new position in shares of Fresenius Medical Care AG & Co. KGaA in the first quarter valued at about $27,000. Brooklyn Investment Group increased its position in shares of Fresenius Medical Care AG & Co. KGaA by 424.5% in the first quarter. Brooklyn Investment Group now owns 1,285 shares of the company's stock valued at $32,000 after acquiring an additional 1,040 shares during the period. Russell Investments Group Ltd. increased its position in shares of Fresenius Medical Care AG & Co. KGaA by 33.3% in the first quarter. Russell Investments Group Ltd. now owns 4,200 shares of the company's stock valued at $105,000 after acquiring an additional 1,049 shares during the period. Finally, TD Private Client Wealth LLC increased its position in shares of Fresenius Medical Care AG & Co. KGaA by 6,380.3% in the second quarter. TD Private Client Wealth LLC now owns 4,925 shares of the company's stock valued at $141,000 after acquiring an additional 4,849 shares during the period. Hedge funds and other institutional investors own 8.37% of the company's stock.

Fresenius Medical Care AG & Co. KGaA Trading Down 1.4%

NYSE:FMS opened at $26.78 on Monday. Fresenius Medical Care AG & Co. KGaA has a one year low of $18.94 and a one year high of $30.46. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.44 and a quick ratio of 1.08. The company's 50-day simple moving average is $25.33 and its 200 day simple moving average is $26.24. The firm has a market capitalization of $15.71 billion, a P/E ratio of 21.95, a PEG ratio of 0.61 and a beta of 0.92.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $0.52 EPS for the quarter, topping the consensus estimate of $0.50 by $0.02. Fresenius Medical Care AG & Co. KGaA had a net margin of 3.39% and a return on equity of 6.75%. The business had revenue of $5.54 billion for the quarter, compared to analyst estimates of $5 billion. As a group, analysts forecast that Fresenius Medical Care AG & Co. KGaA will post 1.51 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. Morgan Stanley restated an "underweight" rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, August 12th. Weiss Ratings raised shares of Fresenius Medical Care AG & Co. KGaA from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Wednesday, October 8th. Zacks Research raised shares of Fresenius Medical Care AG & Co. KGaA from a "hold" rating to a "strong-buy" rating in a research note on Monday, October 6th. Wall Street Zen lowered shares of Fresenius Medical Care AG & Co. KGaA from a "strong-buy" rating to a "buy" rating in a research note on Friday, September 5th. Finally, UBS Group reaffirmed a "sell" rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, September 2nd. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $27.80.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Want to see what other hedge funds are holding FMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.